214 related articles for article (PubMed ID: 25648933)
1. The oncolytic effects of reovirus in canine solid tumor cell lines.
Igase M; Hwang CC; Coffey M; Okuda M; Noguchi S; Mizuno T
J Vet Med Sci; 2015 May; 77(5):541-8. PubMed ID: 25648933
[TBL] [Abstract][Full Text] [Related]
2. The effects of oncolytic reovirus in canine lymphoma cell lines.
Hwang CC; Umeki S; Igase M; Coffey M; Noguchi S; Okuda M; Mizuno T
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():61-73. PubMed ID: 25319493
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.
Igase M; Hwang CC; Kambayashi S; Kubo M; Coffey M; Miyama TS; Baba K; Okuda M; Noguchi S; Mizuno T
Can J Vet Res; 2016 Jan; 80(1):21-31. PubMed ID: 26733729
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic reovirus in canine mast cell tumor.
Hwang CC; Umeki S; Kubo M; Hayashi T; Shimoda H; Mochizuki M; Maeda K; Baba K; Hiraoka H; Coffey M; Okuda M; Mizuno T
PLoS One; 2013; 8(9):e73555. PubMed ID: 24073198
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
6. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
Shmulevitz M; Lee PW
Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
[TBL] [Abstract][Full Text] [Related]
7. Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines.
Hwang CC; Igase M; Okuda M; Coffey M; Noguchi S; Mizuno T
Biochem Biophys Res Commun; 2019 Sep; 517(2):233-237. PubMed ID: 31345575
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.
Pandha HS; Heinemann L; Simpson GR; Melcher A; Prestwich R; Errington F; Coffey M; Harrington KJ; Morgan R
Clin Cancer Res; 2009 Oct; 15(19):6158-66. PubMed ID: 19773377
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.
Garant KA; Shmulevitz M; Pan L; Daigle RM; Ahn DG; Gujar SA; Lee PW
Oncogene; 2016 Feb; 35(6):771-82. PubMed ID: 25961930
[TBL] [Abstract][Full Text] [Related]
11. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
Shmulevitz M; Marcato P; Lee PW
Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
[TBL] [Abstract][Full Text] [Related]
13. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release.
Marcato P; Shmulevitz M; Pan D; Stoltz D; Lee PW
Mol Ther; 2007 Aug; 15(8):1522-30. PubMed ID: 17457318
[TBL] [Abstract][Full Text] [Related]
14. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
[TBL] [Abstract][Full Text] [Related]
16. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery.
Kemp V; Dautzenberg IJC; Limpens RW; van den Wollenberg DJM; Hoeben RC
Viruses; 2017 Sep; 9(10):. PubMed ID: 28934149
[TBL] [Abstract][Full Text] [Related]
18. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic reovirus effectively targets breast cancer stem cells.
Marcato P; Dean CA; Giacomantonio CA; Lee PW
Mol Ther; 2009 Jun; 17(6):972-9. PubMed ID: 19293772
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma.
Igase M; Shibutani S; Kurogouchi Y; Fujiki N; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Mol Ther Oncolytics; 2019 Dec; 15():49-59. PubMed ID: 31650025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
